View Older Stories View More Recent Stories
-
HIMS CLASS NOTICE: Hims & Hers Health, Inc. Investors are Urged to Contact BFA Law before the Imminent August 25 Class Action Deadline
-
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health
-
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMS
-
HIMS INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
ROSEN, A LEADING LAW FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMS
-
HIMS CLASS DEADLINE: Hims & Hers Health, Inc. (HIMS) Shareholders that Suffered Losses are Reminded to Contact BFA Law by Upcoming August 25 Court Deadline
-
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health
-
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMS
-
HIMS INVESTOR NOTICE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Berger Montague Investigates Hims & Hers Health Inc. (HIMS) for Securities Fraud Following Termination of Novo Nordisk Partnership
-
Active options: MSTR COIN HIMS SOFI CRCL META MARA SMCI INTC GOOGL HOOD CORZ MSFT
-
BREAKING: Hims & Hers Health, Inc. (HIMS) has been Sued for Securities Fraud, Investors are Notified to Contact BFA Law before Court Deadline
-
HIMS ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Hims & Hers Health, Inc. Investors
-
Berger Montague Investigates Potential Securities Class Action Against Hims & Hers Health, Inc.
-
LifeMD (LFMD) stock rises on continued Wegovy partnership with Novo Nordisk (NVO)
-
Hims & Hers (HIMS) hires former Robinhood (HOOD) VP of Product Dheeja Kaur as CPO
-
HIMS SECURITIES ALERT: Hims & Hers Health, Inc. Investors are Notified to Contact BFA Law about its Pending Securities Fraud Investigation
-
HIMS INVESTIGATION ALERT: BFA Law Notifies Hims & Hers Health, Inc. Investors with Losses to Contact the Firm about its Securities Fraud Investigation
-
Compounding Crisis: Johnson Fistel's Probe into Hims & Hers' Semaglutide Scandal
-
Hims & Hers Health, Inc. ALERT: Securities Fraud Investigation by Block & Leviton Could Allow HIMS Investors to Recover Losses
-
Deutsche Bank Reiterates Hold Rating on Hims and Hers (HIMS)
-
Morgan Stanley Reiterates Equalweight Rating on Novo Nordisk (NOVOB:DC) (NVO)
-
Hims & Hers (HIMS) CEO responds to Novo Nordisk (NVO) news
-
HIMS Alert: Kehoe Law Firm, P.C. Investigating Potential Securities Fraud Claims on Behalf of Investors of Hims & Hers Health, Inc.
-
Needham Downgrades Hims and Hers (HIMS) to Hold, Removes from Conviction List
-
Hims & Hers Health, Inc. (HIMS) call put ratio 1 call to 1 put with a focus on June 27 weekly options as share price down 28%
-
Truist on Hims and Hers (HIMS): 'we do not believe branded Wegovy was driving any meaningful subscriber or revenue for HIMS'
-
Leerink on Hims and Hers (HIMS): 'stock volatility tied to weight loss has limited the ability to find a fundamentally palatable valuation'
-
Morgan Stanley on Hims and Hers (HIMS): 'The abrupt change could renew concerns over litigation'
-
BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS), PT $28, 'Litigation risk now front and center'
-
Novo Nordisk (NVO) terminates collaboration with Hims & Hers Health (HIMS) due to concerns about their illegal mass compounding and deceptive marketing
-
Hims & Hers stock falls after Novo Nordisk ends weight loss drug pact
-
Hims & Hers Health, Inc. (HIMS) Falls 18% After Pact with Novo Nordisk Ends
-
BofA on Hims and Hers (HIMS), PT $28: 'core revenue growth y/y has slowed sharply'
-
Morgan Stanley on Hims and Hers (HIMS): 'Sharp deceleration in app downloads and web traffic in the month of May'
-
Citi on Hims and Hers (HIMS): 'If HIMS does end up partnering with LLY, in our view it would signal that HIMS is “throwing in the towel” on compounded GLP-1s'
-
Hims and Hers (HIMS) PT Raised to $65 at Needham
-
Morgan Stanley Reiterates Equalweight Rating on Hims and Hers (HIMS)
-
TD Cowen on Hims and Hers (HIMS): 'acquisition of ZAVA reflects its commitment to expand into international markets'
-
Hims & Hers Health, Inc. (HIMS) call put ratio 2.1 calls to 1 put with a focus on June 60, 65 and 70 calls as share price up 4.7%
-
Hims & Hers Health, Inc. (HIMS) Rapidly Selling $6 to a 60 Handle, Remains +675bps on Day
-
Truist on Hims and Hers (HIMS): 'likely has the opportunity to up-sell', 'we believe HIMS is likely to still have financial capacity to announce additional deals'
-
Citi Reiterates Sell Rating on Hims and Hers (HIMS), PT $30
-
Leerink Partners on Hims and Hers (HIMS): 'we do see some execution and integration risk associated with the deal'
-
BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS), 'Core growth in US slowing notably'
-
Hims & Hers Health, Inc. (HIMS) to Acquire ZAVA
-
Hims & Hers Health, Inc. (HIMS) To Acquire European Telehealth Platform Zava - CNBC
-
Hims & Hers Health, Inc. (HIMS) call put ratio 2.2 calls to 1 put with a focus on June 6 weekly calls as share price up 2.3%
-
Hims and Hers (HIMS) to cut over 4% of staff amid strategy shift - Bloomberg
-
Hims & Hers Health, Inc. (HIMS) Introduces 6-Month Wegovy New Customer Offer
